Dr. Kai Pinkernell is the Chief Medical Officer at Glycostem Therapeutics, Oss, The Netherlands, and responsible for Clinical and Regulatory Affairs. Glycostem Therapeutics is a leading clinical-stage company focused on the development of therapeutic, allogeneic off-the-shelf Natural Killer (NK) cells.
Previously, until March 2021, Dr. Pinkernell was Chief Medical Officer, Chief Development officer and managing director at Medigene AG, a clinical stage biotechnology company in Munich, developing personalized T cell-based immunotherapies, where he was responsible for Clinical and Regulatory Affairs, QA and CMC. Prior to this, Dr Pinkernell was Global Head of Clinical Business at Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, leading worldwide clinical marketing, sales and development. Before joining Miltenyi Biotec he was Senior Director of Regenerative Medicine at Cytori Therapeutics Inc., San Diego, USA. During his academic career, he researched cell therapy approaches at Tulane University, New Orleans, USA. and before pursued a residency/fellowship in internal medicine/cardiology at the German Heart Center and Klinikum Rechts der Isar, Technical University, in Munich, Germany. He received his medical degree from the Westfaelische-Wilhems University in Muenster, Germany, and a Master of Business Administration from the Marshall School of Business at the University of Southern California, Los Angeles, USA.